Rhythm Pharmaceuticals (RYTM)
(Delayed Data from NSDQ)
$38.28 USD
+0.13 (0.34%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $38.24 -0.04 (-0.10%) 4:52 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RYTM 38.28 +0.13(0.34%)
Will RYTM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RYTM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RYTM
Moderna (MRNA) Surges 6.2%: Is This an Indication of Further Gains?
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Misses Revenue Estimates
RYTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: ADC Therapeutics SA (ADCT) Q4 Earnings Expected to Decline
Rhythm Pharmaceuticals, Inc. (RYTM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Strength Seen in Puma Biotech (PBYI): Can Its 10.0% Jump Turn into More Strength?
Other News for RYTM
Analyst Expectations For Rhythm Pharmaceuticals's Future
Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Rhythm Pharmaceuticals (RYTM) and Dexcom (DXCM)
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Commit To Purchase Rhythm Pharmaceuticals At $25, Earn 8.6% Annualized Using Options
Jim Cramer Is 'Willing To Let This Pharma Stock Catch Fire,' Advises Not To Sell McKesson